Above all, NCL inactivation suppresses the HDGF-stimulated oncogenic behaviours and PI3K/Akt activities in hepatoma cells, implicating the potential of NCL as a novel therapeutic target for HCC. This evidence concerns the gene AKT1 and hepatocellular carcinoma.